Background : Mucoepidermoid carcinoma (MEC) is the most common primary epithelial malignant salivary gland tumor in both adults and children. Histological grading of MEC is subjective, but plays an important role in predicting patient prognosis. Immunohistochemistry can accurately diagnose diseases and help with treatment and prognosis. The review of this paper was intended to be helpful in the differential diagnosis of mucinous epidermoid carcinoma. Methods : A PubMed search was carried out. Well-known biomarkers for mucoepidermoid carcinoma were searched in PubMed, and their differences with oral squamous cell carcinoma were compared. Results : When PubMed searched “oral mucoepidermoid carcinoma, biomarker”, a total of 241 papers were found, among which cytokeratin(22), Muc1(membrane-bound mucin1, 9), Muc4( membrane-bound mucin4, 6), Muc5ac (membrane-bound mucin5ac, 4), Muc5b (membrane-bound mucin5b, 3), p63 (15), PCNA (15), p53 (20), EGFR (Epidermal growth factor receptor, 21), c-erbB2 (HER2, 14), and pAKT (2) were searched and investigated. The biomarkers retrieved above were compared with those expressed in squamous cell carcinoma. Conclusion : Due to the above biomarkers, it is possible to classify mucoepidermoid carcinoma and differentiate it from other salivary gland tumors or oral squamous cell carcinoma.
The association between the COMT rs4680 (G>A, Val-158-Met) polymorphism and the risk of fibromyalgia has been investigated in previous studies, but the results are controversial. Therefore, a meta-analysis has been performed to confirm the association between COMT rs4680 (G>A, Val-158-Met) polymorphism and the risk of fibromyalgia in this study. Our study includes eleven case-control studies with 2,909 individuals comprised of 1,365 fibromyalgia patients and 1,544 control subjects. The regression analysis was performed using the random effects model or the fixed effects model and OR with the corresponding 95 % CI was calculated for the allele, recessive, dominant, over-dominant, co-dominant 1, and co-dominant 2 model. No statistical significant associations were observed between COMT rs4680 (G>A, Val-158-Met) polymorphism and risk of fibromyalgia in allele model (P-value = 1.00), recessive model (P-value = 1.00), dominant model (P-value = 0.54), co-dominant 1 model (P-value = 1.00) and co-dominant 2 model (P-value = 1.00). In conclusion, our meta-analysis showed that the COMT rs4680(G>A, Val-158-Met) polymorphism might not be genetic risk factor for the fibromyalgia.